Medgenics Inc

Type: Company
Name: Medgenics Inc
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

New Positive Clinical Data Supports Quest Towards Orphan Designations

By Brian Marckx, CFA :Highly Promising Trial Data with Next-Gen Vector, Orphan Indications Revealed. Q3 ResultsRelated Biotechnology, Pharmaceutical and Healthcare NewsOn Tuesday Medgenics Inc. (NYSEMKT: MDGN ) released financial results for Q3 and also ... [Published BioPortfolio - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

New Positive Clinical Data Supports Quest Towards Orphan Designations

Summary We view the new clinical data as highly promising. 2nd-Gen viral vector showing more controlled delivery and longer duration of effect. MDGN reveals three orphan targets, two of which could enter clinical trials in 2015. Highly Promising ... [Published Seeking Alpha - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

TherapeuticsMD Announces Presentation Of Positive Phase 2 On TX-004HR; Advaxis Provides Clinical Update For ADXS-HPV

Below is a look at some of the headlines for companies that made news in the healthcare sector on October 15, 2014.TherapeuticsMD Inc. (NYSE MKT: TXMD) , an innovative women's healthcare company, announced positive results from phase 2 and pharmacokinetic ... [Published BioMedReports - Oct 16 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 1 reports

Pre-Market Earnings Report for October 15, 2014 : BAC, BLK, PNC, ASML, SCHW, STJ, KEY, CBSH, MTG, IGTE, MDGN

The following companies are expected to report earnings prior to market open on 10/15/2014. Visit our Earnings Calendar for a full list of expected earnings releases.Bank of America Corporation ( BAC ) is reporting for the quarter ending September 30, ... [Published Nasdaq - Oct 14 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 2 reports

Medgenics, Inc. Reports Positive Initial Clinical Data And Third Quarter Financial Results

WAYNE, Pa. and MISGAV, Israel, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (the Company), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo ... [Published BioSpace - Oct 15 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

MEDGENICS : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 2.02 Results of Operations and Financial Condition.On October 15, 2014 , Medgenics, Inc. (the "Company") issued a press releaseregarding its financial results for the third quarter of 2014 and initialclinical data from the clinical study of MDGN-201. ... [Published 4 Traders - Oct 15 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Amgen Declares a Head-to-Head Phase III Win for Humira biosimilar; Conatus Reports Acceptance of Abstract for AASLD Meeting

Below is a look at some of the headlines for companies that made news in the healthcare sector on October 8, 2014.Amgen (NASDAQ: AMGN) has claimed  gaining regulatory approval for its biosimilar of Humira, AbbVie's (NYSE: ABBV) megablockbuster anti-inflammatory ... [Published BioMedReports - Oct 09 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

BCLI Gets A Pat On The Back, OXGN At Work, MDGN Rises After Hours

BrainStorm Cell Therapeutics Inc. (BCLI: Quote) has secured FDA's Fast Track product designation for its core technology, NurOwn, which is currently being studied in a randomized, double-blind, placebo-controlled phase II clinical trial in amyotrophic ... [Published RTTNews.com - Oct 08 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 2 reports

Medgenics to Present Initial Clinical Data From MDGN-201 Study at European Society of Gene and Cell Therapy Congress

WAYNE, Pa. and MISGAV, Israel, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their ... [Published Good Day Sacramento - Oct 07 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 2 reports

Medgenics to Announce Third Quarter 2014 Results and Provide Initial Clinical Data on MDGN-201 (EPODURE(TM)) Trial on October 15, 2014

WAYNE, Pa. and MISGAV, Israel, Sept. 24, 2014 (GLOBE NEWSWIRE) -- .Details on the conference call and webcast will be made available one week prior to the call.About Medgenics, Inc.Medgenics is developing an autologous transduced micro-organ system, BioPump™, ... [Published Wall Street Select - Sep 24 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

TransCelerate BioPharma Inc. Publishes Risk-Based Monitoring Recommendations for Central Monitoring and Technology Considerations

TransCelerate's RBM methodology is based on the notion that shifting monitoring processes from an excessive concentration on Source Data Verification (SDV) to comprehensive, risk-driven monitoring that uses a combination of Central, Off-site and On-site ... [Published Industrial Info Financials - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 1 reports

SAGE Therapeutics Appoints Michael F. Cola to the Company's Board of Directors

CAMBRIDGE, Mass., Sept. 16, 2014 (GLOBE NEWSWIRE) -- (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the appointment of Michael ... [Published EMoneyDaily - Sep 16 2014]

Quotes

...Howard Safran, Medical Director of Brown University Oncology Research Group (BrUOG) and principal investigator of the study. "We are now in the process of opening this study at other institutions."
"Additionally, we have developed a novel system for the expression and secretion of small, endogenous peptides," continued Dr. Neil. "This will enable us to address many orphan disease targets, the first of which is GLP-2 (glucagon-like peptide-2) for shortshort bowel syndrome. We look forward to discussing all of these results during our third quarter conference call and webcast."
...statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan, "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur."

More Content

All (15) | News (15) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
New Positive Clinical Data Supports Quest Towar... [Published BioPortfolio - Oct 17 2014]
New Positive Clinical Data Supports Quest Towar... [Published Seeking Alpha - Oct 17 2014]
TherapeuticsMD Announces Presentation Of Positi... [Published BioMedReports - Oct 16 2014]
Medgenics, Inc. Reports Positive Initial Clinic... [Published BioSpace - Oct 15 2014]
Medgenics Reports Positive Initial Clinical Dat... [Published Market Pulse Navigator - Oct 15 2014]
MEDGENICS : Results of Operations and Financial... [Published 4 Traders - Oct 15 2014]
Pre-Market Earnings Report for October 15, 2014... [Published Nasdaq - Oct 14 2014]
Amgen Declares a Head-to-Head Phase III Win for... [Published BioMedReports - Oct 09 2014]
BCLI Gets A Pat On The Back, OXGN At Work, MDGN... [Published RTTNews.com - Oct 08 2014]
Medgenics to Present Initial Clinical Data From... [Published Good Day Sacramento - Oct 07 2014]
Medgenics to Present Initial Clinical Data From... [Published Wall Street Select - Oct 07 2014]
Medgenics to Announce Third Quarter 2014 Result... [Published Wall Street Select - Sep 24 2014]
Medgenics to Announce Third Quarter 2014 Result... [Published CW 50 Detroit - Sep 24 2014]
TransCelerate BioPharma Inc. Publishes Risk-Bas... [Published Industrial Info Financials - Sep 17 2014]
SAGE Therapeutics Appoints Michael F. Cola to t... [Published EMoneyDaily - Sep 16 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.